The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.
 
Ali Raza Khaki
Stock and Other Ownership Interests - Pfizer; Procter & Gamble; Walgreens Boots Alliance
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Marita Zimmerman
No Relationships to Disclose
 
Louis P. Garrison
Leadership - Veritech Corporation; Veritech Corporation
Stock and Other Ownership Interests - Veritech Corporation; Veritech Corporation
Consulting or Advisory Role - Adamas Pharmaceuticals; Genentech; Mallinckrodt; Merck; Novartis; Pfizer; Roche; Takeda; UCB
Research Funding - Adamas Pharmaceuticals; Genentech; Mallinckrodt; Merck; Novartis; Roche Molecular Diagnostics; Takeda; UCB
Travel, Accommodations, Expenses - Adamas Pharmaceuticals; Genentech; Mallinckrodt; Merck; Novartis; Roche; Takeda; UCB
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)